Table 2.
Changes in Diabetes Treatment Satisfaction Questionnaire and Diabetes Therapy‐Related Quality of Life from baseline to week 12
| Lira group (n = 15) | Dula group (n = 16) | P‐value | |||
|---|---|---|---|---|---|
| Previous score | Changes | Previous score | Changes | ||
| DTSQ score | |||||
| Treatment satisfaction | 25.7 ± 8.1 | 0.1 ± 4.7 | 23.1 ± 5.6 | 4.9 ± 5.2 | 0.013 |
| Frequency of hyperglycemia and hypoglycemia | 5.1 ± 2.0 | −0.5 ± 1.8 | 4.9 ± 2.6 | −1.1 ± 1.7 | 0.40 |
| Subscale score | |||||
| No. 1 Current treatment | 4.7 ± 1.3 | −0.07 ± 0.96 | 4.4 ± 1.2 | 0.0 ± 1.5 | 0.89 |
| No. 2 Frequency of hyperglycemia | 2.9 ± 1.6 | 0.5 ± 1.8 | 3.6 ± 1.8 | −0.6 ± 1.4 | 0.069 |
| No. 3 Frequency of hypoglycemia | 2.3 ± 2.1 | −1.1 ± 2.1 | 1.3 ± 1.6 | −0.5 ± 1.5 | 0.66 |
| No. 4 Convenience | 4.1 ± 1.5 | 0.2 ± 1.1 | 3.4 ± 1.5 | 1.8 ± 1.3 | 0.001 |
| No. 5 Flexibility | 4.0 ± 1.7 | 0.07 ± 1.10 | 3.6 ± 1.6 | 1.3 ± 1.4 | 0.014 |
| No. 6 Understanding | 4.3 ± 1.4 | −0.3 ± 1.1 | 4.0 ± 1.1 | 0.6 ± 1.2 | 0.079 |
| No. 7 Recommend | 4.1 ± 1.8 | 0.2 ± 1.3 | 3.9 ± 1.7 | 0.6 ± 1.3 | 0.38 |
| No. 8 Continue | 4.4 ± 1.4 | 0.07 ± 1.03 | 3.8 ± 1.1 | 0.7 ± 1.1 | 0.21 |
| DTR‐QOL score | |||||
| Total score | 63.5 ± 18.0 | −3.7 ± 6.9 | 57.1 ± 16.2 | 8.9 ± 15.1 | 0.007 |
| Subscale score | |||||
| Domain 1 | 68.2 ± 22.0 | −1.5 ± 9.6 | 63.7 ± 21.3 | 9.3 ± 20.0 | 0.024 |
| Domain 2 | 61.4 ± 23.4 | −8.8 ± 13.9 | 46.9 ± 23.2 | 12.1 ± 27.8 | 0.036 |
| Domain 3 | 73.3 ± 31.0 | −1.4 ± 16.2 | 67.4 ± 28.4 | 5.2 ± 19.0 | 0.29 |
| Domain 4 | 57.2 ± 15.6 | −3.3 ± 18.8 | 54.4 ± 19.0 | 4.7 ± 24.4 | 0.16 |
Data are mean ± standard deviation. The P‐value for the comparison of the liraglutide‐ and dulaglutide‐treated groups is stated. DTR‐QOL, Diabetes Therapy‐Related Quality of Life; DTSQ, Diabetes Treatment Satisfaction Questionnaire.